We identified two mutations in the CYP19 gene responsible for aromatase deficiency in an 18-year-old 46,XX female with ambiguous external genitalia at birth, primary amenorrhea and sexual infantilism, and polycystic ovaries. The coding exons, namely exons II-X, of the CYP19 gene were amplified by PCR from genomic DNA and sequenced directy. Direct sequencing of the ampled DNA from the patient revealed two single-base changes, at bp 1303 (C-+ T) and bp 1310 (G -p A) in exon X, which were newly found missense mutations and reulted in codon changes of R435C and C437Y, respectively. Subconlng followed by sequencing confirmed that the patient is a compound heterozygote. The results ofrestriction frgment length polymorphism analysis and direct sequencing of the ampliied exon X DNA from the patient's mother indicate maternal inheritance of the R435C mutation. Transient expression experiments showed that the R435C mutant protein had =1.1% of the activity of the wild type, whereas C437Y was totally inactive. Cysteine-437 is the conserved cysteine in the heme-binding region believed to serve as the fifth coordinating ligand of the heme iron. To our knowledge, this patient is the first adult to have described the cardinal features of a syndrome of aromatase deficiency. Recognition that such defects exist will lead to a better understanding of the role of this enzyme in human development and disea.The biosynthesis ofestrogens from Clg steroids is catalyzed by an enzyme complex known as aromatase, whose activity results in aromatization ofthe A ring of androgens to form the phenolic A ring characteristic of estrogens, with concomitant loss of the Clg angular methyl group (1, 2). This enzyme complex is located in the endoplasmic reticulum of estrogenproducing cells and consists oftwo components. The first is a form of cytochrome P450 named aromatase cytochrome P450 (P450arom), the product of the CYP19 gene (3). The second component, NADPH-cytochrome P450 reductase, a ubiquitous flavoprotein of the endoplasmic reticulum of most cell types, transfers reducing equivalents to the P450arom, which binds the C19 substrate and catalyzes the insertion of oxygen into the molecule, resulting in the formation of C18 estrogens